Módulo 1. Avances en la prevención y control de la insuficiencia cardio-renal

Moderador: Dr. Juan Cosin Sales

 
 
Dra. Coral Suero
  • [ACC 2020] The VICTORIA (Vericiguat Global Study In Subjects With Heart Failure With Reduced Ejection Fraction) Presented by Paul Wayne Armstrong
  • [ACC 2020] Effect Of Sacubitril/Valsartan On NT-proBNP In Patients With Heart Failure And Preserved Ejection Fraction: The PARAGON-HF Trial. Presented by Jonathan Cunningham
  • [AHA 2020] Fidelio-CKD
Dr. José Ignacio Cornago
  • [ASN/Kidney week] DAPA-CKD Subanalisis por etiología de ERC
  • [ESC 2020] DAPA-CKD. Paper Heerspink, et al. + Wheeler, et al.
  • [ASN/Kidney week] DAPA-CKD Subanalisis por Status DM, diurético MRAS
  • [PUBLICACIÓN] Docherty Eur Heart J. 2020. Tratamiento según terapia de base Solomon JACC 2020 Dapa in HFrEF tretaed with Sacubitril/Valsaratan
Dra. Rebeca Reyes
  • [ADA/Paper] DECLARE Renal Outcomes (Paper Mosenzon)
  • [ADA 271-OR] Presidents’ select abstract: Effect of dapagliflozin on the incidence of diabetes: a prespecified exploratory analysis from dapa-HF
  • [EASD 2020] Empagliflozin for the treatment of chronic heart failure and a reduced ejection fraction in patients with and without diabetes: new results of the EMPEROR-Reduced trial
Dra. Elena Fortuny
  • [AHA 2020] Soloist-WHF
  • [AHA 2020] Scored
  • [AHA 2020] GALACTIC-HF de Omecantiv
 
 
 
 

Módulo 2. Anticoagulación y riesgo cardiovascular: nuevas perspectivas

Moderador: Dr. José María Fernández Rodríguez

 
 
Dra. Coral Suero
  • [ACC 2020] The Benefit And Risk Of Rivaroxaban Plus Aspirin In Patients With Peripheral Artery Disease After Lower Extremity Revascularization (LER) With And Without Concomitant Clopidogrel: A Key Subgroup Analysis
  • [ACC 2020] Apixaban For The Treatment Of Venous Thromboembolism Associated With Cancer: The CARAVAGGIO Study. Presented by Giancarlo Agnelli
Dr. José Ignacio Cornago
  • [ESC 2020] Pharmacokinetics of Apixaban in Patients with End Stage Renal Disease on Hemodialysis and Atrial Fibrillation: Results from the RENALAF trial
  • [ESC 2020] Impact of Direct Oral Anticoagulants Compared with Warfarin in Patients on Dialysis: a Metaanalysis
  • [ESC 2020] Differential Effect of Anticoagulation Therapy in Patients Older Versus Younger than 80 Years with atrial Fibrillation and Severe Chronic Kidney Disease
  • [ESC 2020] Clinical Outcome with Noacs vs VKAs in Patients with Atrial Fibrillation and Severe Chronic Kidney Disease: Results of a Retrospective, Multicenter, Realworld Study
Dra. Rebeca Reyes
  • [AHA 2020] Meta-analysis Comparing the Efficacy and Safety of Direct Acting Oral Anticoagulants to Warfarin in Patients with Atrial Fibrillation with and without Diabetes
  • [AHA 2020] Efectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study
  • [AHA 2020] Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Frail Elderly Patients: Insights from the ARISTOPHANES Study
  • [AHA 2020] Association Between Oral Anticoagulants and Osteoporosis: Real-world Data Mining Using a multi-Methodological Approach
  • [ESC 2020] Risk of Fracture in Patients with non-Valvular atrial Fibrillation Initiating Direct Oral Anticoagulants vs. Vitamin K Antagonists
Dra. Elena Fortuny
  • [ESC 2020] Naxos Study: Risk of Bleeding with Oral Anticoagulants in non-Valvular Atrial Fibrillation Patients in France
  • [ESC 2020] Safety and Efficacy of Antithrombotic Therapy According to Stroke and Bleeding Risk in Patients with atrial Fibrillation and Acute Coronary Syndrome or PCI: Insights from AUGUSTUS
  • [ESC 2020]. Rapid Fire Abstracts. Coronary Artery Disease-Treatment. Choice of P2Y12 Inhibitor and Clinical Outcomes in the AUGUSTUS Study: Support for an Individualised Approach
 
 
 
 

Módulo 3. Retos del control lipídico en la prevención del riesgo cardiovascular

Moderador: Dr. Carlos Guijarro

 
 
Dr. Emilio Ortega
  • [EAS 2020] ORION-9. Inclisiran Reduces LDL-Cholesterol Independent of Genotype in Subjects with Heterozygous Familial Hypercholesterolaemia
  • [EAS 2020] ORION-11. Effect of Inclisiran on Atherogenic Lipoproteins in High-Risk Primary Prevention Populations: Analysis from the Phase III ORION-11 Trial
  • [AHA 2020] OMEMI trial. No Benefit with Omega-3 Fatty Acids on CV Outcomes and all-Cause Death in Elderly Patients after MI, Compared to Patients Receiving Placebo
  • [AHA 2020] STRENGHT trial. No Effect of Omega-3 carboxylic Acid on MACE in High-Risk Patients. The STRENGTH Trial, Evaluating the Combination of EPA and DHA, Was Stopped Due to Futility. These Results Are Different than Those of the REDUCE-IT Trial
Dr. José Ignacio Cornago
  • [AHA 2020] Fourier Subestudios
  • [EDTA SO085] Circulating PCSK9 Level Predicts Risk of Cardiovascular Events and Death in Hemodialysis Patients
  • [EDTA P0183] The Use of PCSK9 Inhibitors Could Reduce Proteinuria in Chronic Kidney Disease Patients
Dra. Rebeca Reyes
  • [ESC 2020] The DA VINCI Study: What Have We Learnt from 18 European Countries on Lipid Management
  • [ESC 2020] The DA VINVI Study: Do European Patients with Peripheral Arterial Disease Receive Optimal Lipid Lowering Therapy and Achieve LDL-C Goals? Results from The DA VINCI Study
  • [ESC 2020] The DA VINVI Study: What Is the Potential Cardiovascular Risk Reduction Associated with Achieving LDL-C Levels Recommended in the ESC/EAS Guidelines for Very High Risk Patients? Data from Clinical Practice in 18 European Countries
  • [ESC 2020] BANTING&BERSON Study: Achievement of ESC/EAS Lipid Treatment Goals with Evolocumab in Patients with Type 2 Diabetes: Analyses of the BANTING And BERSON Trials
Dra. Elena Fortuny
  • [AHA 2020 P392] Evolocumab Inhibits the Acute Rise in Lipoprotein(a) in Patients With Non-ST Elevation Myocardial Infarction (NSTEMI)- Results From the EVACS Study
  • [AHA 2020 MP460] Relative Efficacy of Alirocumab, Bempedoic Acid, Evolocumab, Ezetimibe and Inclisiran Added to Statins for Reduction of Low-Density Lipoprotein Cholesterol - A Network Meta-Analysis of Randomized Clinical Trials
 
 
 
 

Módulo 4. El desafío de la diabesidad como factor de riesgo cardiovascular

Moderador: Dr. Javier Escalada San Martín

 
 
Dr. Emilio Ortega
  • [AHA 2020] Semaglutide Reduces MACE Consistently across Baseline Triglyceride Levels in Patients with Type 2 Diabetes: a Post Hoc Analysis of the SUSTAIN 6 and PIONEER 6 Trials
  • [EASD 2020] EASD/EASL Symposium: Is NAFLD a Risk for Health in the Context of Diabetes?
Dr. José Ignacio Cornago
  • [ASN 2020] Effect of Dulaglutide on Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial
  • [ASN 2020] Effects of Semaglutide on CKD Outcomes: a Post Hoc Pooled Analysis from the SUSTAIN 6 and PIONEER 6 Trials
  • [EASD 2020] Renoprotection with Semaglutide and Liraglutide-Direct or Indirect Effects?
  • [ERA-EDTA Congress app] Improving Renal Outcomes in Type 2 Diabetes: A Potential Novel Role for GLP-1 Receptor Agonists
Dra. Rebeca Reyes
  • [ADA 2020] Semaglutide for the treatment of obesity (STEP-programme)
  • [ADA 2020] Which Diet Is Best for Treatment of Diabetes and Obesity?
Dra. Elena Fortuny
  • [ACC 2020] Effects of Semaglutide versus Comparators on Cardiovascular Events Across a Continuum of Baseline Cardiovascular Risk: Combined Analysis of the SUSTAIN and PIONEER trials
  • Alfayez OM. Indirect Comparison of Glucagon Like Peptide-1 Receptor Agonists Regarding Cardiovascular Safety and Mortality in Patients with Type 2 Diabetes Mellitus: Network Meta-Analysis. Cardiovasc Diabetol. 2020; 19(1): 96. doi: 10.1186/s12933-020-01070-z. PMID: 32571416; PMCID: PMC7310317
  • [EASD 2020] Effects of Liraglutide and Semaglutide on Stroke Subtypes in Patients with Type 2 Diabetes: a Post Hoc Analysis of the LEADER, SUSTAIN 6 and PIONEER 6 Trials
  • Zhu J. Association of Glucose-Lowering meDications with Cardiovascular Outcomes: an Umbrella Review and Evidence Map. Lancet Diabetes Endocrinol. 2020; 8(3): 192-205. doi: 10.1016/S2213-8587(19)30422-X. Epub 2020 Jan 29. PMID: 32006518